14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CMPS vs MNMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Mind Medicine (MindMed) Inc. Common Shares (MNMD) is the stronger overall head-to-head candidate over COMPASS Pathways Plc American Depository Shares (CMPS) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CMPS carries a Unified Composite Score of 57.3/100 (HOLD) at $8.30 (N/M Forward P/E, 0.0% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: CMPS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.9); meanwhile MNMD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CMPS vs MNMD. Trailing 12-month operating profitability (CMPS 0.0% vs MNMD 0.0%) and valuation multiples (CMPS N/M vs MNMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CMPS vs MNMD Key Questions & Quantitative Answers
As of Nov 16, 2026, Mind Medicine (MindMed) Inc. Common Shares (MNMD) is the stronger overall head-to-head candidate over COMPASS Pathways Plc American Depository Shares (CMPS) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CMPS carries a Unified Composite Score of 57.3/100 (HOLD) at $8.30 (N/M Forward P/E, 0.0% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CMPS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.9); meanwhile MNMD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MNMD leads the Growth & Scale pillar: CMPS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MNMD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CMPS generates N/A in USD-normalized revenue versus N/A for MNMD. In operating R&D and SG&A reinvestment, CMPS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNMD.
CMPS and MNMD trade at balanced relative valuation multiples. CMPS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CMPS (-296.4% ROE) versus MNMD (-85.6% ROE) capital efficiency.
In options market volatility and institutional positioning, CMPS carries 80.6% implied volatility (16th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 122% Vol realized risk). By comparison, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.